[PDF][PDF] Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280
M Bouma, B Nuijen, DR Stewart… - PDA Journal of …, 2003 - researchgate.net
AP 5280 is a novel polymer-conjugated platinum anticancer agent currently in Phase I
clinical trials. In order to guarantee the quality of AP 5280 drug substance for use in the …
clinical trials. In order to guarantee the quality of AP 5280 drug substance for use in the …
Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum …
SC Van der Schoot, B Nuijen, P Sood… - Die Pharmazie-An …, 2006 - ingentaconnect.com
AP5346 is a low molecular weight polymer-conjugated platinum antineoplastic agent. The
lyophilized drug product has completed a phase I clinical trial. In order to guarantee a …
lyophilized drug product has completed a phase I clinical trial. In order to guarantee a …
Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280
M Bouma, B Nuijen, R Harms, JR Rice… - Drug development …, 2003 - Taylor & Francis
AP 5280 is a novel polymer-conjugated platinum anticancer agent showing promising in
vitro and in vivo activity against solid tumors. The aim of this study was to develop a …
vitro and in vivo activity against solid tumors. The aim of this study was to develop a …
Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential
M Bouma, B Nuijen, DR Stewart, JR Rice… - Anti-cancer …, 2002 - journals.lww.com
AP 5280 is a novel polymer-conjugated platinum anticancer agent currently undergoing
phase I clinical trials. It is pharmaceutically formulated as a lyophilized product containing …
phase I clinical trials. It is pharmaceutically formulated as a lyophilized product containing …
Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent
P Sood, KB Thurmond, JE Jacob, LK Waller… - Bioconjugate …, 2006 - ACS Publications
Syntheses of the novel polymer-bound platinum-based chemotherapeutic agent poly
(HPMA)-GGG-Ama Pt (1 R, 2 R)-DACH, AP5346, and its precursors are reported. The …
(HPMA)-GGG-Ama Pt (1 R, 2 R)-DACH, AP5346, and its precursors are reported. The …
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors
JM Rademaker-Lakhai, C Terret, SB Howell… - Clinical Cancer …, 2004 - AACR
Abstract Purpose: This Phase I study was designed to determine the maximum tolerated
dose, profile of adverse events, and dose-limiting toxicity of AP5280 in patients with solid …
dose, profile of adverse events, and dose-limiting toxicity of AP5280 in patients with solid …
Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models
X Lin, Q Zhang, JR Rice, DR Stewart… - European Journal of …, 2004 - Elsevier
AP5280 is a novel N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-bound platinum
(Pt) therapeutic designed to increase the therapeutic index relative to conventional, small …
(Pt) therapeutic designed to increase the therapeutic index relative to conventional, small …
Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice
T Smit, JR Snyman, EW Neuse, L Bohm… - Anti-cancer …, 2005 - journals.lww.com
The toxicity and distribution of cisplatin and two novel platinum (Pt) polymer conjugates (Pt-6
and Pt-7) were determined in serum and tissue of BALB/c mice at specific time points after ip …
and Pt-7) were determined in serum and tissue of BALB/c mice at specific time points after ip …
Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry
GK Poon, FI Raynaud, P Mistry, DE Odell… - … of Chromatography A, 1995 - Elsevier
Bis (acetato) amminedichloro (cyclohexylamine) platinum (IV)(JM216) is a new orally
administered platinum complex with antitumor properties, and is currently undergoing phase …
administered platinum complex with antitumor properties, and is currently undergoing phase …
HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo
E Gianasi, M Wasil, EG Evagorou, A Keddle… - European Journal of …, 1999 - Elsevier
The aim of this study was to compare in vitro and in vivo HPMA copolymer platinates with
cisplatin in terms of platinum release, toxicity and antitumour activity. N-(2-hydroxypropyl) …
cisplatin in terms of platinum release, toxicity and antitumour activity. N-(2-hydroxypropyl) …